About
Jonathan Douxfils is a Professor at the University of Namur, affiliated with the Namur Research Institute for Life Sciences and the Thrombosis and Hemostasis Center. His expertise lies in pharmacology, thrombosis, and anticoagulant therapies. He holds a Pharm.D. and Ph.D. from the University of Namur and a Master of Pharmacy from Université Catholique de Louvain.
Key roles include CEO of Qualiblood, Co-Chairman of the International Society on Thrombosis and Hemostasis's SSC Control of Anticoagulation, and Pharmacovigilance Expert at the Federal Agency of Medicines and Health Products. His research focuses on anticoagulant safety, thrombosis risk assessment, and innovative diagnostic tools like the DOAC Dipstick.
Notable awards include the Alfers Prize 2022, Eberhard F. Mammen Young Investigator Award 2019, and multiple recognition in hemostasis research. He leads projects such as NucleoGlio (glioblastoma diagnostics) and GT4HEALTH (gene therapy research).
He has supervised 19 thesis works and contributed to over 436 research outputs. His work aligns with UN SDGs in health and innovation.
